|
|
|
|
| LEADER |
03220nam a22005055i 4500 |
| 001 |
978-94-007-2849-3 |
| 003 |
DE-He213 |
| 005 |
20150727051450.0 |
| 007 |
cr nn 008mamaa |
| 008 |
120103s2012 ne | s |||| 0|eng d |
| 020 |
|
|
|a 9789400728493
|9 978-94-007-2849-3
|
| 024 |
7 |
|
|a 10.1007/978-94-007-2849-3
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a R-RZ
|
| 072 |
|
7 |
|a MBGR
|2 bicssc
|
| 072 |
|
7 |
|a MED000000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 610
|2 23
|
| 100 |
1 |
|
|a Prokop, Aleš.
|e author.
|
| 245 |
1 |
0 |
|a Systems Biology in Biotech & Pharma
|h [electronic resource] :
|b A Changing Paradigm /
|c by Aleš Prokop, Seth Michelson.
|
| 264 |
|
1 |
|a Dordrecht :
|b Springer Netherlands,
|c 2012.
|
| 300 |
|
|
|a XVIII, 127 p. 16 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a SpringerBriefs in Pharmaceutical Science & Drug Development,
|x 1864-8118 ;
|v 2
|
| 505 |
0 |
|
|a Abstract -- 1 Introduction: Discovery & Development - New Facet Of Industry, New Tools And Lead Optimization: 1.1 Scope And Content Of This Review -- 2 Discovery: Use Of Systems Biology For Identifying Targets -- 3 Integrative Systems Biology I - Biochemistry: Phase I Lead Discovery & Molecular Interactions -- 4 Integrative Systems Biology Ii - Molecular Biology: Phase 2 Lead Discovery & In Silico Screening -- 5. Discovery: Computational Systems Biology (Csb) In Health & And Disease I -- 6 Development: In Vivo Pharmacology - Systems Biology In Health & Disease Ii -- 7 Development: Pharmacokinetics – Systems Biology In Health & Disease Iii -- 8 Development: Multiscale Csb – Simulation Tools -- 9 Development: Drug Formulation & Delivery -- 10 Development: Preclinical Model Based Drug Development -- 11 Systems Biology: Impact On Pharma And Biotech -- 12 Acknowledgment -- 13 Bibliography.
|
| 520 |
|
|
|a Systems Biology (SB) is a suite of technologies and methodologies that resulted, conceptually from the merging of two basic paradigms, reductionism and holism. It represents a combination of reductionist and holistic approaches to the relationships among the elements of a system, with the goal of identifying its emergent properties and defining, quantitatively, molecular, cellular, tissue, organ and whole body processes. One manifestation of SB is as a tool for hypothesis generation about a system that is typically too large and complex to understand by simple reasoning.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Pharmaceutical technology.
|
| 650 |
|
0 |
|a Biotechnology.
|
| 650 |
|
0 |
|a Microbiology.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Biomedicine general.
|
| 650 |
2 |
4 |
|a Biotechnology.
|
| 650 |
2 |
4 |
|a Applied Microbiology.
|
| 650 |
2 |
4 |
|a Pharmaceutical Sciences/Technology.
|
| 700 |
1 |
|
|a Michelson, Seth.
|e author.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9789400728486
|
| 830 |
|
0 |
|a SpringerBriefs in Pharmaceutical Science & Drug Development,
|x 1864-8118 ;
|v 2
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-94-007-2849-3
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SME
|
| 950 |
|
|
|a Medicine (Springer-11650)
|
